NCT05941104 is a clinical trial of frailty in Prostatic Neoplasms, sponsored by Anhui Provincial Hospital.

Who is sponsoring NCT05941104?

NCT05941104 is sponsored by Anhui Provincial Hospital.

What drugs are being tested in NCT05941104?

Interventions in NCT05941104: frailty.

What condition does NCT05941104 study?

NCT05941104 studies Prostatic Neoplasms, Frailty, Blood Biological Indicators, Quality of Life, Survival.

Is NCT05941104 still recruiting?

NCT05941104 is currently status unknown. Last updated 12 July 2023.

Last reviewed 2023-07-12 · How we verify

NCT05941104

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Frailty on Blood Biology Indicators, Quality of Life and Survival of Patients With Radical Prostatectomy

Status unknown Last updated 12 July 2023

What this trial tests

trial testing frailty in Prostatic Neoplasms in 100 participants. Status unknown.

Timeline

15 July 2023

Primary endpoint
1 July 2025

31 December 2025

Quick facts

Lead sponsor	Anhui Provincial Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	15 July 2023
Primary completion	1 July 2025
Estimated completion	31 December 2025

Drugs / interventions tested

frailty

Conditions studied

Prostatic Neoplasms — all drugs for Prostatic Neoplasms →
Frailty — all drugs for Frailty →
Blood Biological Indicators — all drugs for Blood Biological Indicators →
Quality of Life — all drugs for Quality of Life →

Sponsor

Anhui Provincial Hospital

Who can join

60 and older, male only, with Prostatic Neoplasms or Frailty. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to evaluate the effect of frailty on blood biology indicators, quality of life and survival of patients with radical prostatectomy. The main questions it aims to answer are: 1. Evaluate the impact of frailty on the blood biological indicators, quality of life and survival of patients with radical prostatectomy, specifically. 2. Describe the longitudinal changes in the quality of life of patients with radical prostatectomy. Participants will be divided into frail group or non-frail group based on frailty assessment. Researchers will compare the two groups to see the impact of frailty on the blood biological indicators, quality of life and survival.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of frailty

Trials testing the same drug.

NCT05257226 — Both Short- and Long-term Outcome Differences According to Patient Frailty · recruiting

Other recruiting trials for Prostatic Neoplasms

Currently open trials in the same condition.

NCT07285057 — Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance · Phase 2 · recruiting
NCT07319871 — A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer · Phase 1 · recruiting
NCT07335224 — Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture · NA · recruiting
NCT07451002 — A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France · recruiting
NCT06547398 — Prostate Adaptive Radiation Therapy · NA · recruiting

Other Anhui Provincial Hospital trials

Trials by the same sponsor.

NCT07523464 — Centrally Confined 8Gy/1f to Tumor Core Followed by Concurrent Chemoradiotherapy for Unresectable Stage III NSCLC · Phase 1 · not yet recruiting
NCT07481656 — Effects of Recombinant Human Growth Hormone in Elderly Patients With Moderate to Severe Acute Brain Injury (GH-ABI-RCT) · Phase 4 · not yet recruiting
NCT07462676 — Simultaneous Vs Staged VPS and CP :A Multi-cnter RCT. · NA · not yet recruiting
NCT07211048 — Anti CD19 Gene Therapy for B-cell Lymphoma · NA · recruiting
NCT07279844 — An Open-label, Observational, Long-term Follow-up Study Evaluating the Safety and Efficacy of RGL-193 Putamen Injection · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05941104 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Anhui Provincial Hospital
Last refreshed: 12 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05941104.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing